Nitrofurans as novel anti-tuberculosis agents: identification, development and evaluation

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Tuberculosis Research

Background:

• A commercial library screen identified a nitrofuranyl amide as a hit compound for tuberculosis (TB) treatment.
• The hit compound showed potential for novel mechanisms of action against both active and latent TB bacteria.

Purpose of the Study:

• To optimize the lead nitrofuranyl amide compound into potent anti-tuberculosis agents.
• To address limitations in solubility, bioavailability, and in vivo efficacy through iterative synthesis and structure-activity relationship studies.

Main Methods:

• Iterative synthesis of compound libraries (three generations) based on the nitrofuranyl amide scaffold.
• Structure-activity relationship (SAR) analysis to guide optimization.
• In vitro and in vivo testing to evaluate anti-tuberculosis activity, solubility, and bioavailability.

Main Results:

• First-generation optimization yielded compounds with increased anti-TB activity but poor solubility and limited in vivo efficacy.
• Second-generation compounds with hydrophilic cyclic secondary amines and benzyl piperazine substitutions showed improved solubility and potent in vitro activity.
• Third-generation compounds were synthesized to block metabolic sites, addressing rapid metabolism observed in second-generation leads.

Conclusions:

• Iterative optimization of the nitrofuranyl amide scaffold is a viable strategy for developing novel anti-tuberculosis agents.
• Balancing in vitro potency, solubility, bioavailability, and metabolic stability is crucial for successful drug development against tuberculosis.